BioSpace News Archive

PictorLabs emerged from stealth mode Thursday with $18.8 million to advance its AI-powered virtual staining platform that researchers hope will “reimagine the future” of histopathology.

SQZ Biotechnologies is slashing 60% of its workforce and looking for a new CEO after initiating a strategic prioritization to focus on its cell therapy platform for solid tumors.

Pfizer and Roivant have joined forces to form yet another Vant. The new entity will initially work to commercialize RVT-3101 for ulcerative colitis.

Eli Lilly’s investigational antibody donanemab met all of its primary and secondary endpoints in the Phase III TRAILBLAZER-ALZ 4 study, the company announced Wednesday.

Athira Pharma’s experimental Alzheimer’s therapy, fosgonimeton, continues to show signs of being able to improve cognition and function in patients.

Pfizer Inc. and Valneva SE reported antibody persistence data six months after the completion of a three-dose or a two-dose vaccination schedule with their Lyme disease vaccine candidate, VLA15 in both children and adults.

Innate Pharma SA announced that three posters showcasing IPH5201 and IPH5301 will be presented on December 8 at the 2022 European Society for Medical Oncology I-O Annual Congress in Geneva, Switzerland.

OKYO Pharma Limited, an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in the multi-billion-dollar dry eye disease market, announces that the board of directors of the Company, has appointed PKF Littlejohn LLP as its new independent auditor with immediate effect.

RetinAI Medical AG (“RetinAI”), a leader in developing software solutions for image processing and artificial intelligence in Ophthalmology, is proud to launch Discovery CORE™ with AI for retinal fluid and layer segmentation. Discovery CORE and its AI models have been designed to accelerate data analysis and help clinical and academic researchers collaborate more efficiently, in real time, with their peers, on medical and imaging datasets.

France’s Gustave Roussy Institute, Europe’s leading cancer center and ranked third in the world according to Newsweek Magazine, has chosen to partner with Synapse Medicine, a leader in clinical pharmacy and medication reconciliation.